JavaScript NENÍ povolen !

Prosím povolte JavaScript.

Článek

PubMed

Záznam pochází z PubMed

Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab

Szturz, Petr
Autor Szturz, Petr Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium. petr.szturz@fnbrno.cz Department of Internal Medicine, Hematology and Oncology, School of Medicine, University Hospital Brno and Masaryk University, Brno, Czech Republic. petr.szturz@fnbrno.cz
Specenier, Pol
Autor Specenier, Pol Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
Van Laer, Carl
Autor Van Laer, Carl Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium Department of Otorhinolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium
Van Den Weyngaert, Danielle
Autor Van Den Weyngaert, Danielle Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium Department of Radiotherapy, University Radiotherapy Antwerp, Antwerp, Belgium
Corthouts, Bob
Autor Corthouts, Bob Department of Radiology, Antwerp University Hospital, Edegem, Belgium
Carp, Laurens
Autor Carp, Laurens Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium
Van Marck, Eric
Autor Van Marck, Eric Department of Pathology, Antwerp University Hospital, Edegem, Belgium
Vanderveken, Olivier
Autor Vanderveken, Olivier Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium Department of Otorhinolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium
Vermorken, Jan B
Autor Vermorken, Jan B Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

European archives of oto-rhino-laryngology. 2016 Jun ; 273 (6) : 1629-36. [epub] 20150605

Eur Arch Otorhinolaryngol
ISSN 1434-4726 | 0937-4477
Zdroj

Jazyk angličtina Země Německo Médium print-electronic

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz https://www.medvik.cz/link/pmid26044403

PubMed 26044403
DOI 10.1007/s00405-015-3673-y
PII: 10.1007/s00405-015-3673-y
Knihovny.cz E-zdroje

Klíčová slova
Epidermal growth factor receptor inhibitor, Positron emission tomography, Targeted therapy, Taxanes, Tonsil cancer,
MeSH
časové faktory MeSH
cetuximab aplikace a dávkování MeSH
cisplatina aplikace a dávkování MeSH
docetaxel MeSH
fluoruracil aplikace a dávkování MeSH
indukce remise MeSH
kvalita života MeSH
lidé středního věku MeSH
lidé MeSH
lokální recidiva nádoru diagnostické zobrazování farmakoterapie MeSH
nádory hlavy a krku diagnostické zobrazování farmakoterapie MeSH
PET/CT MeSH
přežití bez známek nemoci MeSH
protokoly protinádorové kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
spinocelulární karcinom diagnostické zobrazování farmakoterapie MeSH
taxoidy aplikace a dávkování MeSH
tonzilární nádory diagnostické zobrazování farmakoterapie MeSH
výsledek terapie MeSH
Check Tag
lidé středního věku MeSH
lidé MeSH
mužské pohlaví MeSH
Publikační typ
časopisecké články MeSH
kazuistiky MeSH
Názvy látek
cetuximab MeSH
cisplatina MeSH
docetaxel MeSH
fluoruracil MeSH
taxoidy MeSH

BACKGROUND: In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. METHODS: In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. RESULTS: As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. CONCLUSIONS: Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.

Department of Internal Medicine Hematology and Oncology School of Medicine University Hospital Brno and Masaryk University Brno Czech Republic

Department of Medical Oncology Antwerp University Hospital Wilrijkstraat 10 2650 Edegem Belgium

Department of Nuclear Medicine Antwerp University Hospital Edegem Belgium

Department of Otorhinolaryngology and Head and Neck Surgery Antwerp University Hospital Edegem Belgium

Department of Pathology Antwerp University Hospital Edegem Belgium

Department of Radiology Antwerp University Hospital Edegem Belgium

Department of Radiotherapy University Radiotherapy Antwerp Antwerp Belgium

Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium

Zobrazit více v PubMed

Clin Cancer Res. 2006 Sep 1;12(17):5064-73 PubMed

Cancer. 2001 Apr 1;91(7):1316-23 PubMed

PLoS One. 2014 Aug 08;9(8):e103918 PubMed